You are here

Tagrisso

Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

Endpoints

clinical trials

Flag link:

Genprex to progress Phase I/II trial of non-small cell lung cancer therapy

Genprex to progress Phase I/II trial of non-small cell lung cancer therapy

Clinical Trials Arena

clinical trials

non-small cell lung cancer

Flag link:

AstraZeneca pushes forward with Tagrisso combos, touting PhII data with Hutchmed drug

AstraZeneca pushes forward with Tagrisso combos, touting PhII data with Hutchmed drug

Endpoints

clinical trials

Flag link:

AstraZeneca staves off last Tagrisso copycat with settlement—for now

AstraZeneca staves off last Tagrisso copycat with settlement—for now

Fierce Pharma

Alembic Pharmaceuticals

Flag link:

Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication

Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication

Endpoints

non-small cell lung cancer

Flag link:

AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial

AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial

BioSpace

clinical trials

non-small cell lung cancer

Flag link:

#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?

#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?

Endpoints

non-small cell lung cancer

Flag link:

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

Pharmaceutical Business Review

patritumab deruxtecan

non-small cell lung cancer

clinical trials

Flag link:

Cut-price drug venture takes aim at Pfizer and Astrazeneca

Cut-price drug venture takes aim at Pfizer and Astrazeneca

EP Vantage

Flag link:

In pilot of patient-reported outcomes project, FDA hopes to encourage ‘more rigorous’ data collection

In pilot of patient-reported outcomes project, FDA hopes to encourage ‘more rigorous’ data collection

MedCity News

clinical trials

Flag link:

ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama

ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama

Pharmaforum

Bristol-Myers Squibb

Flag link:

AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

Motley Fool

Flag link:

AstraZeneca bid to expand lung cancer drug's use boosted by trial data

AstraZeneca bid to expand lung cancer drug's use boosted by trial data

BioPharma Dive

clinical trials

Flag link:

AstraZeneca to unveil key data for cancer drugs at ASCO

AstraZeneca to unveil key data for cancer drugs at ASCO

Pharmaforum

colorectal cancer

Flag link:

AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy

AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy

Endpoints

clinical trials

non-small cell lung cancer

Flag link:

Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful

Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful

Fierce Pharma

EGFR lung cancer

Flag link:

ESMO: AstraZeneca eyes payer boost with Tagrisso's latest survival win

ESMO: AstraZeneca eyes payer boost with Tagrisso's latest survival win

Fierce Pharma

EGFR lung cancer

Flag link:

AZ gets China nod for Tagrisso in first-line lung cancer

AZ gets China nod for Tagrisso in first-line lung cancer

Pharmaforum

non-small cell lung cancer

Flag link:

AstraZeneca cancer drugs build as primary care shrinks

AstraZeneca cancer drugs build as primary care shrinks

Biopharma Dive

Flag link:

AstraZeneca's flagship Tagrisso helps lung cancer patients live longer in pivotal study

AstraZeneca's flagship Tagrisso helps lung cancer patients live longer in pivotal study

Endpoints

EGFR-mutated NSCLC

Flag link:

Pages